Gillmore Staging (ATTR Amyloidosis) Calculator

Gillmore Staging (ATTR Amyloidosis): Explanation and Clinical Context Gillmore staging is a validated system to stratify prognosis in patients with transthyretin (ATTR) cardiac amyloidosis, using serum NT-proBNP and renal function (eGFR) as key predictors. Stage 1 corresponds to NT-proBNP < 3000 ng/L and eGFR > 45 mL/min/1.73m², indicating the lowest risk group. Stage 2 includes patients who meet only one of the above criteria (either NT-proBNP > 3000 ng/L or eGFR < 45 mL/min/1.73m²), representing intermediate risk.

Stage 3 applies to patients with both NT-proBNP > 3000 ng/L and eGFR < 45 mL/min/1.73m², representing the highest risk group. This tool helps clinicians with risk stratification, management decisions, and prognostication for ATTR cardiac amyloidosis.